Rüfer CE, Glatt H, Kulling SE (2006). “Structural elucidation of hydroxylated metabolites of the isoflavan equol by gas chromatography-mass spectrometry and high-performance liquid chromatography-mass spectrometry”. Drug Metab. Dispos.34 (1): 51-60. doi:10.1124/dmd.105.004929. PMID16199471.
“High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart”. Br. J. Nutr.94 (6): 873–876. (2005). doi:10.1079/bjn20051565. PMID16351761.
“Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor {α} (ER{α}) and ERβ in human cells”. Toxicol. Sci.80 (1): 14–25. (2004). doi:10.1093/toxsci/kfh147. PMID15084758.
Lampe, JW; Karr, SC; Hutchins, AM; Slavin, JL (1998). “Urinary equol excretion with a soy challenge: influence of habitual diet”. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine217 (3): 335–9. doi:10.3181/00379727-217-44241. PMID9492344.
Rowland, IR; Wiseman, H; Sanders, TA; Adlercreutz, H; Bowey, EA (2000). “Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora”. Nutr. Cancer36 (1): 27–32. doi:10.1207/S15327914NC3601_5. PMID10798213.
Arai, Y; Uehara, M; Sato, Y; Kimira, M; Eboshida, A; Adlercreutz, H; Watanabe, S (March 2000). “Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake”. Journal of Epidemiology / Japan Epidemiological Association10 (2): 127–35. doi:10.2188/jea.10.127. PMID10778038.
Akaza, H; Miyanaga, N; Takashima, N; Naito, S; Hirao, Y; Tsukamoto, T; Fujioka, T; Mori, M et al. (February 2004). “Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents”. Japanese Journal of Clinical Oncology34 (2): 86–9. doi:10.1093/jjco/hyh015. PMID15067102.
Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S; Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group (2003). “Soy, isoflavones, and breast cancer risk in Japan”. J. Natl. Cancer. Inst.95 (12): 906-913. doi:10.1093/jnci/95.12.906. PMID12813174.
Kokubo Y, Iso H, Ishihara J, Okada K, Inoue M, Tsugane S; JPHC Study Group (2007). “Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I”. Circulation116 (22): 2553-2562. doi:10.1161/CIRCULATIONAHA.106.683755. PMID18025534.
Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S; Japan Public Health Center-Based Prospective Study Group (2007). “Soy product and isoflavone consumption in relation to prostate cancer in Japanese men”. Cancer Epidemiol. Biomarkers Prev.16 (3): 538-545. doi:10.1158/1055-9965.EPI-06-0517. PMID17337648.
Setchell, KD; Zhao, X; Shoaf, SE; Ragland, K (2009). “The pharmacokinetics of S-(−)equol administered as SE5-OH tablets to healthy postmenopausal women”. J. Nutr.139 (11): 2037–43. doi:10.3945/jn.109.110874. PMID19776178.
国立がん研究センターがん予防・検診研究センター 予防研究部 (2003年). “大豆・イソフラボン摂取と乳がん発生率との関係について”. JPHC Study 厚生労働省研究班による多目的コホート研究. 2011年3月10日閲覧。
国立がん研究センターがん予防・検診研究センター 予防研究部 (2007年). “イソフラボンと脳梗塞・心筋梗塞発症との関連について”. JPHC Study 厚生労働省研究班による多目的コホート研究. 2011年3月10日閲覧。
国立がん研究センターがん予防・検診研究センター 予防研究部 (2007年). “大豆製品・イソフラボン摂取量と前立腺がんとの関連について”. JPHC Study 厚生労働省研究班による多目的コホート研究. 2011年3月10日閲覧。
nih.gov
pubmed.ncbi.nlm.nih.gov
Rüfer CE, Glatt H, Kulling SE (2006). “Structural elucidation of hydroxylated metabolites of the isoflavan equol by gas chromatography-mass spectrometry and high-performance liquid chromatography-mass spectrometry”. Drug Metab. Dispos.34 (1): 51-60. doi:10.1124/dmd.105.004929. PMID16199471.
“High concordance of daidzein-metabolizing phenotypes in individuals measured 1 to 3 years apart”. Br. J. Nutr.94 (6): 873–876. (2005). doi:10.1079/bjn20051565. PMID16351761.
“Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor {α} (ER{α}) and ERβ in human cells”. Toxicol. Sci.80 (1): 14–25. (2004). doi:10.1093/toxsci/kfh147. PMID15084758.
Setchell, KD; Borriello, SP; Hulme, P; Kirk, DN; Axelson, M (September 1984). “Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease”. Am. J. Clin. Nutr.40 (3): 569–78. PMID6383008.
Setchell, KD; Brown, NM; Lydeking-Olsen, E (December 2002). “The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones”. The Journal of Nutrition132 (12): 3577–84. PMID12468591.
Atkinson, C; Frankenfeld, CL; Lampe, JW (2005). “Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health”. Experimental Biology and Medicine (Maywood, N.J.)230 (3): 155–70. PMID15734719.
Lampe, JW; Karr, SC; Hutchins, AM; Slavin, JL (1998). “Urinary equol excretion with a soy challenge: influence of habitual diet”. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine217 (3): 335–9. doi:10.3181/00379727-217-44241. PMID9492344.
Setchell, KD; Cole, SJ (2006). “Method of defining equol-producer status and its frequency among vegetarians”. J Nutr.136 (8): 2188–93. PMID16857839.
Rowland, IR; Wiseman, H; Sanders, TA; Adlercreutz, H; Bowey, EA (2000). “Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora”. Nutr. Cancer36 (1): 27–32. doi:10.1207/S15327914NC3601_5. PMID10798213.
Watanabe, S; Yamaguchi, M; Sobue, T; Takahashi, T; Miura, T; Arai, Y; Mazur, W; Wähälä, K et al. (October 1998). “Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (kinako)”. The Journal of Nutrition128 (10): 1710–5. PMID9772140.
Arai, Y; Uehara, M; Sato, Y; Kimira, M; Eboshida, A; Adlercreutz, H; Watanabe, S (March 2000). “Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake”. Journal of Epidemiology / Japan Epidemiological Association10 (2): 127–35. doi:10.2188/jea.10.127. PMID10778038.
Akaza, H; Miyanaga, N; Takashima, N; Naito, S; Hirao, Y; Tsukamoto, T; Fujioka, T; Mori, M et al. (February 2004). “Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents”. Japanese Journal of Clinical Oncology34 (2): 86–9. doi:10.1093/jjco/hyh015. PMID15067102.
Song, KB; Atkinson, C; Frankenfeld, CL; Jokela, T; Wähälä, K; Thomas, WK; Lampe, JW (May 2006). “Prevalence of daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and girls”. The Journal of Nutrition136 (5): 1347–51. PMID16614428.
Setchell, KD; Cole, SJ (2006). “Method of defining equol-producer status and its frequency among vegetarians”. The Journal of Nutrition136 (8): 2188–93. PMID16857839.
Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S; Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group (2003). “Soy, isoflavones, and breast cancer risk in Japan”. J. Natl. Cancer. Inst.95 (12): 906-913. doi:10.1093/jnci/95.12.906. PMID12813174.
Kokubo Y, Iso H, Ishihara J, Okada K, Inoue M, Tsugane S; JPHC Study Group (2007). “Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I”. Circulation116 (22): 2553-2562. doi:10.1161/CIRCULATIONAHA.106.683755. PMID18025534.
Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S; Japan Public Health Center-Based Prospective Study Group (2007). “Soy product and isoflavone consumption in relation to prostate cancer in Japanese men”. Cancer Epidemiol. Biomarkers Prev.16 (3): 538-545. doi:10.1158/1055-9965.EPI-06-0517. PMID17337648.
Setchell, KD; Clerici, C; Lephart, ED; Cole, SJ; Heenan, C; Castellani, D; Wolfe, BE; Nechemias-Zimmer, L et al. (2005). “S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora”. Am. J. Clin. Nutr.81 (5): 1072–9. PMID15883431.
Setchell, KD; Zhao, X; Shoaf, SE; Ragland, K (2009). “The pharmacokinetics of S-(−)equol administered as SE5-OH tablets to healthy postmenopausal women”. J. Nutr.139 (11): 2037–43. doi:10.3945/jn.109.110874. PMID19776178.
